A 5-Year Observational Study of Patients With Treatment-Resistant Depression Treated With Vagus Nerve Stimulation or Treatment as Usual: Comparison of Response, Remission, and Suicidality
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The Treatment-Resistant Depression Registry investigated whether adjunctive vagus nerve stimulation (VNS) with treatment as usual in depression has superior long-term outcomes compared with treatment as usual only. METHOD: This 5-year, prospective, open-label, nonrandomized, observational registry study was conducted at 61 U.S. sites and included 795 patients who were experiencing a major depressive episode (unipolar or bipolar depression) of at least 2 years' duration or had three or more depressive episodes (including the current episode), and who had failed four or more depression treatments (including ECT). Patients with a history of psychosis or rapid-cycling bipolar disorder were excluded. The primary efficacy measure was response rate, defined as a decrease of ≥50% in baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score at any postbaseline visit during the 5-year study. Secondary efficacy measures included remission. RESULTS: Patients had chronic moderate to severe depression at baseline (the mean MADRS score was 29.3 [SD=6.9] for the treatment-as-usual group and 33.1 [SD=7.0] for the adjunctive VNS group). The registry results indicate that the adjunctive VNS group had better clinical outcomes than the treatment-as-usual group, including a significantly higher 5-year cumulative response rate (67.6% compared with 40.9%) and a significantly higher remission rate (cumulative first-time remitters, 43.3% compared with 25.7%). A subanalysis demonstrated that among patients with a history of response to ECT, those in the adjunctive VNS group had a significantly higher 5-year cumulative response rate than those in the treatment-as-usual group (71.3% compared with 56.9%). A similar significant response differential was observed among ECT nonresponders (59.6% compared with 34.1%). CONCLUSIONS: This registry represents the longest and largest naturalistic study of efficacy outcomes in treatment-resistant depression, and it provides additional evidence that adjunctive VNS has enhanced antidepressant effects compared with treatment as usual in this severely ill patient population.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, stimulation of the vagus nerve (one of the core interoceptive neural pathways) has been successfully used as a means of treating depression (Aaronson et al., 2017).”
From Atypical interoception as a common risk factor for psychopathology: A review (2021) · cites this paper as Aaronson et al., 2017
In the citing paper
“This was even the case in patients with comorbid depression and anxiety who are frequent non-responders in trials on antidepressant drugs.”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [116]
In the citing paper
“Further, a 5-year prospective observational study which compared the effects of treatment as usual and VNS as adjunctive treatment with treatment as usual only in treatment-resistant depression, showed a better clinical outcome and a higher remission rate in the VNS group (116).”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [116]
Citations
Cites
1 retracted
Hollon, S. D., DeRubeis, R. J., Fawcett, J., Amsterdam, J. D., Shelton, R. C., Zajecka, J., Young, P. R., & Gallop, R. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1054 · Cited by 179 · cited 1×
“Given ethical concerns about following such a severely ill patient population over a 5-year period, the registry had a naturalistic, observational design and did not randomly assign patients to the treatment groups (22, 23).”
Self-citationRetractedThe central role of the propensity score in observational studies for causal effects
ROSENBAUM, P. R., & RUBIN, D. B. (1983) · Biometrika · doi:10.1093/biomet/70.1.41 · Cited by 31,241
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1976) · Medical Entomology and Zoology · Cited by 8,899
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
A Diagnostic Interview: The Schedule for Affective Disorders and Schizophrenia
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,684 · cited 1×
“TheMontgomeryÅsberg Depression Rating Scale (MADRS) (12) (administered by central raters), the Quick Inventory of Depressive Symptomatology–Self Report (QIDS-SR) (13, 14), the CGI improvement (CGI-I) score, and the patient-rated Frequency, Intensity, andBurdenofSideEffectsRating scale (15) were administered, and data…”
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 10×
“Secondary efficacy endpoints included response based on a CGI-I score of 1 or 2 at a postbaseline visit and an improvement of$50% frombaseline on theQIDS-SR; remission, based on aMADRS score #9 at a postbaseline visit, a QIDS-SR score #5 at a postbaselinevisit, andaCGI-I scoreof 1 at apostbaselinevisit; and duration o…”
MethodInfluentialThe Central Role of the Propensity Score in Observational Studies for Causal Effects
Rosenbaum, P. R., & Rubin, D. B. (1983) · Biometrika · doi:10.2307/2335942 · Cited by 3,261
Research works printed but not linked: 2
- Rush AJ, 2009, CNS Drugs, 23, 627
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
Cited by
Items 101–200 of 391
Rush, A. J., Conway, C. R., Aaronson, S. T., George, M. S., Riva‐Posse, P., Dünner, D. L., Zajecka, J., Bunker, M. T., Quevedo, J., Allen, R. M., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.12.1187 · Cited by 27
“Conway et al. [47], in a post hoc analysis using outcome data from a VNS registry, reported that patients receiving VNS had greater improvements in QoL than patients who received TAU (defined as any antidepressant treatment, including ECT) [48].”
Self-citationGadeyne, S., Mertens, A., Carrette, E., den Bossche, F. V., Boon, P., Raedt, R., & Vonck, K. E. J. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.11.079 · Cited by 28
Vagus Nerve Stimulation in Treatment-Resistant Depression: A Case Series of Long-Term Follow-up
Pigato, G., Rosson, S., Bresolin, N., Toffanin, T., Sambataro, F., Olivo, D., Perini, G., Causin, F., Denaro, L., Landi, A., et al. (2022) · Journal of Ect · doi:10.1097/yct.0000000000000869 · Cited by 28
A Systematic Review of Neuromodulation Treatment Effects on Suicidality
Kucuker, M. U., Almorsy, A. G., Sonmez, A. I., Ligezka, A. N., Doruk Camsari, D., Lewis, C. P., & Croarkin, P. E. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.660926 · Cited by 25
“A study by Aaronson et al. (2017) showed that active VNS was associated with a significant decrease in suicidal ideation as measured by the QIDS-SR item 10 and also in suicidal behavior (gesture and attempt) as measured by an investigator-completed suicidality assessment (Aaronson et al., 2017).”
MethodInfluentialBu, Y., Liang, A., Hoffman, B. U., Schiehser, D. M., Case, O., Simmons, A. N., Klaming, R., Gottfried‐Blackmore, A., Mittal, R. K., Puleo, C., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70109 · Cited by 26
Vagus Nerves Stimulation: Clinical Implication and Practical Issue as a Neuropsychiatric Treatment
Jung, B., Yang, C., & Lee, S. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1101 · Cited by 26
“…long-term benefit of VNS that is not noticeable with only short-term use of VNS. Cumulative effects of VNS for TRD was also revealed in a 5-year prospective, nonrandomized study with a large sample of 795 TRD patients [55], where a 5-year cumulative response rate of adjunctive VNS group (67.6”
BackgroundInfluentialClosed-loop vagal nerve stimulation for intractable epilepsy: A single-center experience
Winston, G. M., Guadix, S. W., Lavieri, M. T., Uribe-Cardenas, R., Kocharian, G., Williams, N., Sholle, E., Grinspan, Z. M., & Hoffman, C. E. (2021) · Seizure · doi:10.1016/j.seizure.2021.03.030 · Cited by 24
Mahoney, J. J., Koch-Gallup, N., Scarisbrick, D. M., Berry, J. H., & Rezai, A. R. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120253 · Cited by 25
Aaronson, S. T., & Conway, C. R. (2018) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2018.05.001 · Cited by 27
Self-citationVagus Nerve Stimulation: Back to the Future
Bremner, J. D., & Rapaport, M. H. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040422 · Cited by 24
“In this issue, Aaronson and colleagues (1) present compelling data from a 5-year observational study from the Treatment-Resistant Depression Registry, comparing two cohorts of patients with treatment-resistant depression, one that received implanted vagus nerve stimulation (VNS) therapy and another that either decline…”
BackgroundAaronson, S. T., Goldwaser, E. L., Kutzer, D. J., McAllister-Williams, H., Sackeïm, H. A., & Rush, A. J. (2020) · Journal of Ect · doi:10.1097/yct.0000000000000724 · Cited by 25
“Beyond the standard psychometrics for treatment responsiveness, quality of life in the registry participants was also found to significantly improve in the VNS-TAU group compared with the TAU group.(4,6) Critically, the exceptionally high rate of clinical benefit in ECT responsive patients with bipolar and unipolar DT…”
ResultSelf-citationYi, S., Wang, Z., Yang, W., Huang, C., Liu, P., Chen, Y., Zhang, H., Zhao, G., Li, W., Fang, J., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1018387 · Cited by 23
“VNS has superior clinical results and higher remission rates in MDD treatment (Schlaepfer et al., 2008; Aaronson et al., 2017).”
BackgroundGonda, X., Döme, P., Serafini, G., & Pompili, M. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108390 · Cited by 22
Neurosurgical neuromodulation therapy for psychiatric disorders
Ranjan, M., Mahoney, J. J., & Rezai, A. R. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00366 · Cited by 22
“[115].”
Sigurdardottir, G. A., Nielsen, P. M., Rønager, J., & Wang, A. G. (2019) · Brain and Behavior · doi:10.1002/brb3.1399 · Cited by 26
“A recent 5‐year observational study of patients with treatment‐resistant depression treated with VNS or treatment as usual has provided additional evidence that adjunctive VNS has enhanced antidepressant effects compared with treatment as usual (Aaronson et al., 2017; Rush et al., 2005).”
BackgroundLengvenytė, A., Strumila, R., Maïmoun, L., Sénèque, M., Olié, É., Lefebvre, P., Renard, É., Courtet, P., & Guillaume, S. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01180-x · Cited by 22
“Meanwhile, in a 5-year followup study, vagal stimulation resulted in reduced depressive symptomatology and suicidality [52], suggesting vagal nerve involvement in their pathophysiology.”
BackgroundBalzekas, I., Sladky, V., Nejedlý, P., Brinkmann, B. H., Crepeau, D., Mívalt, F., Gregg, N. M., Attia, T. P., Marks, V. S., Wheeler, L., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.702605 · Cited by 22
George, M. S. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070800 · Cited by 21
Electroconvulsive therapy: still the gold standard for highly treatment-resistant mood disorders
Goldberg, J. F. (2021) · CNS Spectrums · doi:10.1017/s1092852921000110 · Cited by 22
McAllister-Williams, H., Bulmer, S., Newton, K. S., Heath, K., Cousins, D. A., & Currie, A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.020 · Cited by 21
Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder
Lee, Y. K., Gold, M. S., & Fuehrlein, B. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120094 · Cited by 21
Stimulation du nerf vague dans le traitement de la dépression
Senova, S., Rabu, C., Beaumont, S., Michel, V., Palfi, S., Mallet, L., & Domenech, P. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.10.019 · Cited by 25
Timing Considerations for Noninvasive Vagal Nerve Stimulation in Clinical Studies.
Gurel, N. Z., Gazi, A. H., Scott, K. L., Wittbrodt, M. T., Shah, A. J., Vaccarino, V., Bremner, J. D., & Inan, O. T. (2019) · PubMed Central · Cited by 21
Toward Closed-Loop Electrical Stimulation of Neuronal Systems: A Review
Tanskanen, J. M. A., Ahtiainen, A., & Hyttinen, J. (2020) · Bioelectricity · doi:10.1089/bioe.2020.0028 · Cited by 21
Shivaswamy, T., de Souza, R. R., Engineer, C. T., & McIntyre, C. K. (2022) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20220007 · Cited by 27
“Moreover, a five-year study demonstrated that patients who were given VNS as a treatment for depression showed better clinical responses than patients in the treatmentas-usual group, including a higher cumulative response rate [102].”
BackgroundConway, C. R., Aaronson, S. T., Sackeïm, H. A., Duffy, W. J., Stedman, M., Quevedo, J., Allen, R. M., Riva‐Posse, P., Berger, M. A., Alva, G., et al. (2024) · Brain stimulation · doi:10.1016/j.brs.2024.03.016 · Cited by 19
Self-citationDual-Device Neuromodulation in Epilepsy
Freund, B. E., Grewal, S. S., Middlebrooks, E. H., Garcia, D. P. M., Feyissa, A. M., & Tatum, W. O. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.02.057 · Cited by 19
The Future of Brain Stimulation Treatments
Caulfield, K. A., & George, M. S. (2018) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2018.05.004 · Cited by 21
Xia, H., Liu, Z., Liang, W., Zeng, X., Yang, Y., Chen, P., Zhong, Z., & Ye, Q. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/1079129 · Cited by 22
“In addition, VNS has already been approved to treat refractory epilepsy and drug-resistant depression [19, 20].”
BackgroundAntidepressant efficacy and side effect burden: an updated guide for clinicians
Kutzer, T., Dick, M., Scudamore, T., Wiener, M., & Schwartz, T. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-2-2 · Cited by 19
Self-citationTrottier-Duclos, F., Jodoin, V. D., Fournier‐Gosselin, M., Richer, F., Desjardins, N., Tieu, S., & Lespérance, P. (2018) · Journal of Ect · doi:10.1097/yct.0000000000000485 · Cited by 20
“Furthermore, Aaronson's study showed that in the TAU group only 30% reach remission and 40% have response during the 5 years of follow-up.(5) Hence, we are inclined to think the improvement we report on both QOL and clinical symptoms reflects an effect of VNS treatment and not only the effect of time.”
BackgroundMethodNeuromodulation technologies improve functional recovery after brain injury: From bench to bedside
Liu, M., Meng, Y., Ouyang, S., Zhai, M., Yang, L., Yang, Y., & Wang, Y.-H. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00652 · Cited by 18
Himes, L. M., Mayberg, H. S., Husain, M. M., Holtzheimer, P. E., Lozano, A. M., Kennedy, S. H., Gross, R. E., Kopell, B. H., Figee, M., Slavin, K. V., et al. (2025) · Brain stimulation · doi:10.1016/j.brs.2025.08.017 · Cited by 17
Vagusnervstimulation bei schwer zu behandelnden Depressionen
Reif-Leonhard, C., Reif, A., Baune, B. T., & Kavakbasi, E. (2022) · Der Nervenarzt · doi:10.1007/s00115-022-01282-6 · Cited by 19
Neuroimmune interactions and kidney disease
Hasegawa, S., Inoue, T., & Inagi, R. (2019) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.19.014 · Cited by 18
“[71] Aaronson ST, Sears P, Ruvuna F, et al.”
BackgroundMethodLam, J., Williams, M., Ashla, M. M., & Lee, D. J. (2021) · Epilepsy Research · doi:10.1016/j.eplepsyres.2021.106591 · Cited by 20
Abdominal vagal deafferentation alters affective behaviors in rats
Klarer, M., Weber‐Stadlbauer, U., Arnold, M., Langhans, W., & Meyer, U. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.015 · Cited by 17
Sackeïm, H. A., Aaronson, S. T., Bunker, M. T., Conway, C. R., George, M. S., McAllister-Williams, H., Prudic, J., Thase, M. E., Young, A. H., & Rush, A. J. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.05.046 · Cited by 17
Self-citationCheng, C., Xue, X., Jiao, Y., Du, M., Zhang, M., Zeng, X., Sun, J., Qin, W., Deng, H., & Yang, X. (2024) · Psychophysiology · doi:10.1111/psyp.14744 · Cited by 17
“…(George et al., 2000) and has been widely applied to various clinical conditions such as epilepsy (Guberman, 2004; Ryvlin et al., 2021), depression (Aaronson et al., 2017; Fang et al., 2016), cognitive impairment (Wang et al., 2022), functional dyspepsia (Shi et al., 2024), and systemic lupus…”
Kim, J. S., Kim, D. Y., Jo, H. J., Hwang, Y., Song, J. Y., Yang, K. I., & Hong, S. B. (2021) · Journal of Clinical Neurology · doi:10.3988/jcn.2021.17.3.385 · Cited by 16
Gorgulho, A. A., Fernandes, F. D. S., Damiani, L. P., Barbosa, D. A. N., Cury, A., Lasagno, C. M., Bueno, P. R. T., Santos, B. F. O., Santos, R. H. N., Berwanger, O. B., et al. (2018) · Neurosurgery · doi:10.1093/neuros/nyy420 · Cited by 16
Gurel, N. Z., Jiao, Y., Wittbrodt, M. T., Ko, Y., Hankus, A. N., Driggers, E. G., Ladd, S. L., Shallenberger, L. H., Murrah, N. V., Huang, M., et al. (2020) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2020.100012 · Cited by 16
Sackeim, H. A., Dibué, M., Bunker, M. T., & Rush, A. J. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s286977 · Cited by 15
Self-citationCardiovascular disease and depression: a bidirectional relationship and its clinical implications
Wu, J., Tian, Z., Qi, Z., Liu, X., & Yu, P. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1675680 · Cited by 16
Obesity and Depression: Common Link and Possible Targets
Jitte, S., Keluth, S., Bisht, P., Wal, P., Singh, S., Murti, K., & Kumar, N. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273291985240430074053 · Cited by 15
Gurel, N. Z., Shandhi, M. M. H., Bremner, J. D., Vaccarino, V., Ladd, S. L., Shallenberger, L. H., Shah, A. J., & Inan, O. T. (2018) · Wearable and Implantable Body Sensor Networks · doi:10.1109/bsn.2018.8329663 · Cited by 15
“These studies also demonstrate that the need for surgical implantation, ongoing monitoring and care, high-cost, and the inability to provide guaranteed effects for all patients lead to unwillingness to have the VNS therapy [8, 9].”
Kucia, K. A., Merk, W., Zapałowicz, K., & Mędrala, T. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s217816 · Cited by 16
Efficacy of transcutaneous vagus nerve stimulation as treatment for depression: A systematic review
Guerriero, G., Wartenberg, C., Bernhardsson, S., Gunnarsson, S., Ioannou, M., Liljedahl, S., Magnusson, K., Svanberg, T., & Steingrímsson, S. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100233 · Cited by 18
Kraus, C., Quach, D., Sholtes, D. M., Kavakbasi, E., De Zwaef, R., Dibué, M., Zajecka, J., & Baune, B. T. (2022) · Neuromodulation: Technology at the Neural Interface · doi:10.1016/j.neurom.2021.12.010 · Cited by 14
Self-citationThe Role of the Gut-Brain Axis in Diseases
Chen, J. W., Xu, Y., & Cao, P. (2025) · Physiology · doi:10.1152/physiol.00016.2025 · Cited by 18
Neurotherapeutic Interventions for Psychiatric Illness
Dougherty, D. D., & Widge, A. S. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000174 · Cited by 14
Self-citationWest, C. L., Amin, J. Y., Farhin, S., Stanisz, A. M., Mao, Y., & Kunze, W. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00955 · Cited by 14
Ginn, C., Patel, B., & WALKER, R. E. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1609473 · Cited by 16
“7%) in the VNS treatment group compared with those undergoing their usual treatment [37].”
ResultXiang, X.-J., Sun, L.-Z., Xu, C.-B., Xie, Y., Pan, M.-Y., Ran, J., Hu, Y., Nong, B.-X., Shen, Q., Huang, H., et al. (2020) · Journal of Neurorestoratology · doi:10.26599/jnr.2020.9040016 · Cited by 15
“VNS has been proven as a promising neuromodulatory electroceutical in the treatment of medically intractable epilepsy [26] and drug‐resistant depression [27] and holds potential for the management of a wide range of neuropsychiatric disorders by reversing the pathological brain plasticity [28, 29].”
BackgroundYrondi, A., Bennabi, D., Haffen, É., Quélard, D., Samalin, L., Maruani, J., Allauze, E., Pierre, D., Bougerol, T., Camus, V., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10120962 · Cited by 16
“With fewer prospective cohorts of patients with TRD [21,22], there is a lack of data on this specific population.”
BackgroundDvorak, L., Bloemhof‐Bris, E., Shelef, A., Halperin, D., Wexler, G., Talmon, O., & Feffer, K. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.04.008 · Cited by 14
Adjunctive Vagus Nerve Stimulation for Treatment-Resistant Depression: a Quantitative Analysis
Zhang, X., Qing, M.-J., Rao, Y.-H., & Guo, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09726-5 · Cited by 13
A narrative review on invasive brain stimulation for treatment-resistant depression
Dandekar, M. P., Díaz, A. P., Rahman, Z., da Silva, R. H., Nahas, Z. H., Aaronson, S. T., Selvaraj, S., Fenoy, A. J., Sanches, M., Soares, J. C., et al. (2022) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2021-1874 · Cited by 13
Self-citationVagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Moeller, S., Lücke, C., Heinen, C., Bewernick, B. H., Aydın, M., Lam, A. P., Grömer, T. W., Philipsen, A., & Müller, H. (2019) · Journal of Visualized Experiments · doi:10.3791/58264 · Cited by 13
Trapp, N. T., Xiong, W., & Conway, C. R. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_157 · Cited by 15
Self-citationJing, W., Bi, C., Fang, Z., Qian, C., Chen, J., Yu, J., Tian, G., Ye, M., & Liu, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114855 · Cited by 14
Kabotyanski, K. E., Najera, R. A., Banks, G. P., Sharma, H., Provenza, N. R., Hayden, B. Y., Mathew, S. J., & Sheth, S. A. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02951-7 · Cited by 13
“In TRD patients, particularly the severely treatment-resistant population eligible for DBS, the likelihood of response to TAU is inevitably even lower with each passing year [41, 69].”
BackgroundSarasso, P., Tschacher, W., Schoeller, F., Francesetti, G., Roubal, J., Gecele, M., Sacco, K., & Ronga, I. (2024) · Physics of Life Reviews · doi:10.1016/j.plrev.2024.09.005 · Cited by 13
“Indeed, interoceptive awareness [240 – 244] and intero-ceptive cortex activation atypicalities were observed in depression [245 – 247], these being generally interpreted as the consequences of the attempt to reduce negative affect (pain and sadness in our second clinical example in Table 1) by…”
Wang, C., Wu, B., Lin, R., Cheng, Y., Huang, J., Chen, Y., & Bai, J. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1516242 · Cited by 13
Sharma, B., Jones, K. A., Lober, R. M., & Hatcher-Solis, C. N. (2025) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2025.1609654 · Cited by 12
Rosson, S., Bresolin, N., D’Amico, A., Denaro, L., Landi, A., Sambataro, F., & Pigato, G. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120483 · Cited by 12
Conway, C. R., Rush, A. J., Aaronson, S. T., Bunker, M. T., Gordon, C., George, M. S., Riva‐Posse, P., Allen, R. M., Nahas, Z. H., Kriedt, C. L., et al. (2026) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaf080 · Cited by 13
“Studies of longer-term outcomes in MDD hav e typically restricted follow-up to patients meeting response or remission criteria at an acute end point, including previous durability studies of VNS. 17,18 To match these thresholds, the durability analyses were repeated, restricting the sample to those who met SB or remis…”
InfluentialSelf-citationVlaicu, A., & Vlaicu, M. B. ̆. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1779751 · Cited by 12
Die Vagusnervstimulation bei konservativ therapierefraktärer Epilepsie und Depression
Möbius, H., & Welkoborsky, H. (2022) · Laryngo-Rhino-Otologie · doi:10.1055/a-1660-5591 · Cited by 17
“[29] Aaronson ST, Sears P, Ruvuna F et al.”
BackgroundDemyttenaere, K., Costa, T., Kavakbasi, E., Jiang, M., Scheltens, A., Dibué, M., Hall, B., Andrade, P., McAllister-Williams, H., Baune, B. T., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.10.054 · Cited by 12
Acute effect of vagus nerve stimulation (VNS) on brain function
Kavakbasi, E., Groß, J., Wollbrink, A., Fellmeth, R. H., & Baune, B. T. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.06.042 · Cited by 12
Sackeïm, H. A., Rush, A. J., Greco, T., Jiang, M., Badejo, S., Bunker, M. T., Aaronson, S. T., Conway, C. R., Demyttenaere, K., Young, A. H., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291722003798 · Cited by 12
“In some reports on long-term outcomes, a separate group of 159 patients who completed a D-21 protocol were added to the D-23 registry sample (Aaronson et al., 2017).”
BackgroundMethodInfluentialSelf-citationHerzfrequenzvariabilität – Stand der Forschung und klinische Anwendbarkeit
Fouradoulas, M., von Känel, R., & Schmid, J. (2019) · Praxis · doi:10.1024/1661-8157/a003206 · Cited by 17
Synchronized cervical VNS with accelerated theta burst TMS for treatment resistant depression
George, M. S., Caulfield, K. A., O’Leary, K., Badran, B. W., Short, E. B., Huffman, S. M., Li, X., Kerns, S. E., & Williams, N. (2020) · Brain stimulation · doi:10.1016/j.brs.2020.08.002 · Cited by 13
“Cervical VNS can effectively treat medication resistant epilepsy [2,3] and treatment resistant depression over the course of many years [4,5].”
BackgroundŁysik, A., Logoń, K., Szczygieł, A., Wołoszczak, J., Wrześniewska, M., & Leszek, J. (2025) · GeroScience · doi:10.1007/s11357-025-01615-8 · Cited by 11
“Additionally, VNS was associated with lower all-cause mortality and an anti-suicidal effect [83, 84].”
He, L., Wang, J., Zhang, L.-J., Wang, F., Dong, W., & Yang, H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00696 · Cited by 13
George, M. S., Caulfield, K. A., & Wiley, M. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00028-x · Cited by 15
Treatment resistant depression in elderly
Wang, S.-C., Yokoyama, J. S., Tzeng, N., Tsai, C.-F., & Liu, M. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2023.02.004 · Cited by 14
Fabbri, R., Spennato, D., Conte, G., Konstantoulaki, A., Lazzarini, C., Saracino, E., Nicchia, G. P., Frigeri, A., Zamboni, R., Spray, D. C., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108403 · Cited by 12
Moazzami, K., Pearce, B. D., Gurel, N. Z., Wittbrodt, M. T., Levantsevych, O. M., Huang, M., Shandhi, M. M. H., Herring, I., Murrah, N. V., Driggers, E. G., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.09.015 · Cited by 11
Jiakai, H., Jinling, Z., Wang, Y., Li, S., Jiliang, F., Zhang, S., Yanan, Z., Weihang, Z., Deqiang, G., Ran, L., et al. (2023) · PubMed Central · doi:10.19852/j.cnki.jtcm.20230308.002 · Cited by 13
Xie, Z.-F., Wang, S., Gao, Y., Zhang, Y.-D., Han, Y., Huang, J., Gao, M.-N., & Wang, C.-G. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05091-0 · Cited by 11
“BDNF has been implicated in successful memory consolidation and has positive effects on treatment-resistant depression [169, 170, 191, 192].”
Pan, D., Jiang, M. C., Wang, Y., He, J., Tang, J., Liu, S., Li, M., Jiang, X., & Xu, Q. (2025) · Neurobiology of Stress · doi:10.1016/j.ynstr.2025.100777 · Cited by 11
“Given the central role of the VN within the MGB axis, invasive vagus nerve stimulation (VNS) has emerged as a promising therapeutic approach for patients with treatment-resistant depression (Aaronson et al., 2017).”
Aaronson, S. T., Sackeïm, H. A., Jiang, M., Badejo, S., Greco, T., Bunker, M. T., Conway, C. R., Demyttenaere, K., Young, A. H., McAllister-Williams, H., et al. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231209837 · Cited by 10
“This study compared a range of potential outcome metrics in their ability to distinguish treatment conditions already known to differ in clinical outcome, i.e. VNS coupled with TAU vs TAU alone (Aaronson et al., 2017).”
BackgroundMethodResultInfluentialSelf-citationSalloum, N. C., Gott, B. M., & Conway, C. R. (2017) · Brain stimulation · doi:10.1016/j.brs.2017.06.001 · Cited by 11
Self-citationIn vivo closed-loop control of a locust’s leg using nerve stimulation
Zurita, F., Duca, F. D., Teshima, T., Hiendlmeier, L., Gebhardt, M., Luksch, H., & Wolfrum, B. L. (2022) · Scientific Reports · doi:10.1038/s41598-022-13679-z · Cited by 10
Moeller, S., Wang, R., Aydın, M., Lam, A. P., Sitter, A., Grüter, J., Philipsen, A., & Müller, H. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.08.071 · Cited by 10
“Long-term follow-ups indicate fewer suicide attempts, lower levels of suicidal ideations and thoughts, and fewer hospitalizations in patients treated with VNS in addition to pharmacotherapy compared to patients with the same level of depression symptom severity who were only treated with pharmacotherapy [2,4,7].”
BackgroundReducing suicidal ideation by biofeedback-guided respiration – heart rate coherence
Jelinek, H. F., & Khandoker, A. H. (2020) · Digital Psychiatry · doi:10.1080/2575517x.2020.1732733 · Cited by 10
“in addressing treatment-resistant depression [43].”
Hu, M. X., Palantza, C., Setkowski, K., Gilissen, R., Karyotaki, E., Cuijpers, P. J., Riper, H. M., Beurs, D. P. D., Nuij, C., Christensen, H. M., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-037566 · Cited by 11
Adjunctive vagus nerve stimulation for treatment-resistant depression: a preliminary study
Zhang, X., Guo, Y., Ning, Y., Cao, L., Rao, Y.-H., Sun, J., Qing, M.-J., & Zheng, W. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2021.2019789 · Cited by 10
“Several controlled studies examining the therapeutic efficacy and safety of adjunctive VNS for TRD have been published, but with inconsistent findings (Rush, Sackeim et al. 2005; Sperling et al. 2009; Aaronson et al. 2017).”
MethodResultTan, G., Chen, H., & Leuthardt, E. C. (2025) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2025.08.001 · Cited by 10
Neuromodulation Strategies in Lifelong Bipolar Disorder: A Narrative Review
Bernabei, L., Leone, B., Hirsch, D., Mentuccia, V., Panzera, A., Riggio, F., Sangiovanni, L., Piserchia, V., Nicolò, G., & Pompili, E. (2024) · Behavioral Sciences · doi:10.3390/bs14121176 · Cited by 13
“This evaluation should encompass not only the primary neurological or psychiatric condition but also any comorbidities that may influence treatment outcomes or pose contraindications [32] (see Table 3).”
Neurobiological Mechanisms Underlying Psychological Dysfunction After Brain Injuries
Unadkat, P., Rebeiz, T. J., Ajmal, E., Souza, V. D., Xia, A., Jinu, J., Powell, K., & Li, C. (2025) · Cells · doi:10.3390/cells14020074 · Cited by 9
Perugi, G., Calò, P., Filippis, S. D., Rosso, G., Vita, A., Adami, M., Ascione, G., Morrens, J., & Delmonte, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.769693 · Cited by 9
Kim, W. J., Lee, Y., Hong, K. H., Choi, S., Song, J., & Hwang, H.-J. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1593614 · Cited by 9
Privacy and Ethical Concerns of Brain-Computer Interfaces
Yue, C. (2023) · IEEE International Conference on Metaverse Computing, Networking and Applications (MetaCom) · doi:10.1109/metacom57706.2023.00036 · Cited by 10
“[5].”
Kavakbasi, E., & Baune, B. T. (2024) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2023.12.004 · Cited by 8
Kavakbasi, E., Assche, E. V., Schwarte, K., Hohoff, C., & Baune, B. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084196 · Cited by 9
“In the VNS registry, the median time to first response in the VNS group was 12 months [26].”
BackgroundZhang, W., Mou, Z., Zhong, Q., Liu, X., Lan, Y., Gou, L., Chen, Z., So, K., & Zhang, L. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1393549 · Cited by 9
Vagus nerve stimulation for the therapy of Dravet syndrome: a systematic review and meta-analysis
Chen, S., Li, M., & Huang, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1402989 · Cited by 10
Metadata
- Authors
- Aaronson, S. T., Sears, P., Ruvuna, F., Bunker, M., Conway, C. R., Dougherty, D. D., Reimherr, F. W., Schwartz, T. L., & Zajecka, J. M.
- Affiliations
- Rush University Medical Center (US)
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2017-07-01
- Volume
- 174
- Issue
- 7
- Pages
- 640-648
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2599051175
- Cited by
- 381
- References
- 26
- Citations by year
- 2026: 36 · 2025: 42 · 2024: 54 · 2023: 34 · 2022: 40 · 2021: 39 · 2020: 43 · 2019: 47 · 2018: 37 · 2017: 8
- FWCI
- 18.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Vagus Nerve Stimulation Research
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- treatment-resistant depression, vagus nerve stimulation, adjunctive therapy, response rate, remission, suicidality, bipolar depression, major depressive disorder, long-term outcomes
- MeSH terms
- Adult, Bipolar Disorder, Chronic Disease, Depressive Disorder, Major, Major Depressive Disorder, Electroconvulsive Therapy, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Registries, Treatment Outcome, Vagus Nerve Stimulation, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.